ZAI LAB LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.91 USD | +1.08% |
|
+13.08% | -41.79% |
ETFs positioned on Zai Lab Limited
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.29% | 4 M€ | -27.92% | ||
| 1.04% | 2 M€ | -16.59% | - | |
| 0.75% | 96 M€ | -.--% | - | |
| 0.27% | 0 M€ | 0.00% | - | |
| 0.21% | 0 M€ | 0.00% | - | |
| 0.07% | 35 M€ | -5.85% | - | |
| 0.03% | 117 M€ | +1.11% | - | |
| 0.01% | 31 M€ | +3.50% | - | |
| 0.00% | 7 M€ | +1.95% | - | |
| 0.00% | 34 M€ | +4.85% | - | |
| 0.00% | 389 M€ | +6.83% | - | |
| 0.00% | 39 M€ | +3.67% | - | |
| 0.00% | 302 M€ | +3.80% | - | |
| 0.00% | 7 M€ | +0.11% | - | |
| 0.00% | 147 M€ | +4.88% | - | |
| 0.00% | 108 M€ | +2.03% | - | |
| 0.00% | 17 M€ | +0.50% | - | |
| 0.00% | 15 M€ | +11.24% | ||
| 0.00% | 52 M€ | -0.60% | - | |
| 0.00% | 8 M€ | -1.35% | - |
Zai Lab Ltd is a holding company mainly engaged in the biopharmaceutical field. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including oncology, autoimmune and infectious diseases fields. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include Niraparib (ZL-2306), ZL-2103, ZL-1101 and others.
Sector
Pharmaceuticals
Calendar
2024-05-07
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
15.91
USD
Average target price
52.5
USD
Spread / Average Target
+230.01%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -41.79% | 1.55B | |
| -4.66% | 87.53B | |
| +1.32% | 40.42B | |
| -19.27% | 29.48B | |
| +57.86% | 25.43B | |
| -17.69% | 11.49B | |
| -43.00% | 11.3B | |
| -9.14% | 11.1B | |
| +5.24% | 8.75B | |
| -8.42% | 7.99B |
- Stock Market
- Equities
- ZLAB Stock
- Funds and ETFs Zai Lab Limited
